Related Experiment Videos
Growth hormone treatment in children before and after renal transplantation
1Department of Pediatrics, Sophia Children's Hospital, Erasmus University, Rotterdam, The Netherlands.
Insights
Recombinant human growth hormone (GH) therapy significantly improves growth in children with chronic kidney disease and after kidney transplants. This treatment shows promise for enhancing final height in pediatric patients experiencing growth failure.
Area of Science:
- Pediatric Nephrology
- Endocrinology
- Growth Disorders
Background:
- Growth failure is a significant challenge for children with chronic renal disease, impacting approximately 75% of pediatric renal allograft recipients who achieve final height below the third percentile.
- Growth retardation is a common complication in pediatric patients with chronic renal failure and post-renal transplantation.
Purpose of the Study:
- To evaluate the efficacy and safety of recombinant human growth hormone (GH) therapy in improving growth in children with chronic renal disease and post-renal transplantation.
- To determine if GH therapy can improve the final height of pediatric patients experiencing growth failure secondary to renal conditions.
Main Methods:
- Treatment with recombinant human growth hormone (GH) at a dose of 28-30/m2/week was administered to pediatric patients.
- Growth acceleration and bone maturation were monitored during the intermediate term of therapy.
Main Results:
- Recombinant human growth hormone (GH) therapy significantly accelerated growth in patients with growth retardation due to chronic renal failure and after renal transplantation.
- No adverse effects or acceleration of bone maturation were observed during the intermediate term of GH therapy.
Conclusions:
- Recombinant human growth hormone (GH) therapy is an effective treatment for accelerating growth in pediatric patients with chronic renal disease and post-transplant.
- GH therapy holds potential for improving the final height of children suffering from growth failure related to renal conditions.
Abstract:
Growth failure is a major problem for many children with chronic renal disease. For approximately 75% of pediatric renal allograft recipients final height falls below the third percentile. In the intermediate term, recombinant human growth hormone (GH) therapy at a dose of 28-30/m2/week accelerates growth significantly in patients with growth retardation secondary to chronic renal failure and after renal transplantation, without evidence of adverse effects or acceleration of bone maturation. Therefore, GH therapy may well improve final height of these patients.